Clinical trials: Depressive Symptoms
Depression, Depressive Disorder
Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder
The main objective of this study is to compare the antidepressant efficacy and safety of DVS-233 SR versus placebo in adult outpatients with Major Depressive Disorder.
- Conditions
- Depression, Depressive Disorder, Major Depressive Disorder
- Trial name
- NCT00092911
- Testing
- DVS-233 SR
- Volunteers
- 244 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02218008
- Testing
- ALKS 5461
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 407 people
- Sponsor
- Alkermes, Inc.
Major Depressive Disorder
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders
The purpose of this study is to demonstrate superior efficacy of Quetiapine fumarate sustained release (SEROQUEL) compared with placebo when used as a mono-therapy in the treatment of Major Depressive Disorders PLEASE NOTE…
- Trial name
- OPAL (NCT00326144)
- Testing
- Quetiapine fumarate
- Where
- 34 sites in United States
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Depression, Post-Traumatic Stress Disorder
Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention
Background: Current military involvement in Afghanistan (Operation Enduring Freedom - OEF) and Iraq (Operation Iraqi Freedom - OIF) has created unforeseen burdens on the mental health and well-being of US service women and men.
- Conditions
- Depression, Post-Traumatic Stress Disorder, Functional Status
- Trial name
- NCT01231711
- Testing
- Vets Prevail
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Prevail Health Solutions, LLC
Depressive Disorder, Depression
Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder
This is a double-blind, sham controlled, multi-center study to confirm the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) for the treatment of patients currently experiencing an episode of depression…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Depressive Episode
- Trial name
- NCT03288714
- Testing
- Synchronized Transcranial Magnetic Stimulation (sTMS)
- Where
- 14 sites in United States
- Volunteers
- 121 people
- Sponsor
- Wave Neuroscience
Depressive Disorder, Major
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder.
- Trial name
- NCT00384033
- Testing
- Desvenlafaxine Succinate Sustained-Release (DVS SR), Duloxetine 60 mg/day
- Where
- 22 sites in United States
- Volunteers
- 638 people
- Sponsor
- Pfizer
Major Depressive Disorder
Open Label Optimization Study
The goal of this observational study is to demonstrate effectiveness in the treatment of Major Depressive Disorder The primary objective is to assess the effectiveness in the treatment of Major Depressive Disorder using the CGI-I…
- Trial name
- OLO (NCT05819021)
- Testing
- SAINT® Neuromodulation System (NMS)
- Where
- 7 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Magnus Medical
Depressive Disorder, Major
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
The purpose of this research is to learn more about a new treatment for individuals with Major Depressive Disorder (MDD) with heightened symptoms of anhedonia (i.e. loss of pleasure or interest in activities).
- Trial name
- NCT06982820
- Testing
- Prism Training
- Where
- 3 sites in United States, Israel
- Volunteers
- 170 people
- Sponsor
- GrayMatters Health Ltd.
Depressive Disorder
Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors
This study is designed to evaluate the efficacy and safety in depressive patients who did not respond sufficiently to selective serotonin re-uptake inhibitors (SSRI).
- Trial name
- NCT00296517
- Testing
- 323U66 (Bupropion Hydrochloride Sustained Release)
- Where
- 62 sites in Japan
- Volunteers
- 325 people
- Sponsor
- GlaxoSmithKline
Schizophrenia, Depression
Quetiapine Extended Release Depression Symptoms
Aim of the study is to assess if the new compound Seroquel XR™ is non-inferior to Risperidone, considered as the reference drug for the treatment of depressive symptoms of schizophrenia.
- Trial name
- ExAttitude (NCT00640562)
- Testing
- Quetiapine Extended Release, Risperidone
- Where
- 21 sites in Italy
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Depressive Disorder, Major
Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
The purpose of this study is to evaluate the effect of the Dialogues Time to Talk program in subjects treated with Venlafaxine Extended Release (ER).
- Trial name
- NCT00401726
- Testing
- Venlafaxine ER, Dialogues Time to Talk Program
- Where
- 44 sites in United States
- Volunteers
- 537 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depression
Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects
The purpose of this study is to determine the effect of a single dose infusion of AZD 6765 compared with placebo and ketamine on the blood oxygen level dependent signal using fMRI (functional Magnetic Resonance Imaging) in…
- Trial name
- NCT01046630
- Testing
- AZD6765, Ketamine
- Where
- 2 sites in United Kingdom
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Major Depressive Disorder
Major Depressive Disorder With Mixed Features - Extension
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features…
- Trial name
- RESOLVE3 (NCT01423253)
- Testing
- Lurasidone
- Where
- 17 sites in United States
- Volunteers
- 48 people
- Sponsor
- Sumitomo Pharma America, Inc.
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant
The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improving the depressive symptoms in adult participants with major depressive disorder…
- Trial name
- VENTURA-7 (NCT06514742)
- Testing
- Aticaprant
- Where
- 84 sites in United States, Belgium and 7 more
- Volunteers
- 101 people
- Sponsor
- Janssen Research & Development, LLC
Depression, Depressive Disorder
Digital Therapeutic for Adolescent Depressive Symptoms in Hematology, Oncology, and Weight Management
The primary aims of the proposed research are to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for the…
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Episode
- Trial name
- NCT05351866
- Testing
- CBT-based mobile intervention for depression, Mobile control with education about depression
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Limbix Health, Inc.
Depressive Disorder, Major
A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)
The purpose of this study is to determine whether the Cervel Neurotech rTMS device is safe and effective in the treatment of depression in people who do not get better with antidepressant medications or cannot take antidepressant…
- Trial name
- NCT01909232
- Testing
- Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator, Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
- Where
- 6 sites in United States
- Volunteers
- 92 people
- Sponsor
- Cervel Neurotech, Inc.
Depressive Disorder, Depression
GW679769 In Fibromyalgia
The purpose of the study is to investigate safety, tolerability and efficacy of oral GW679769 up to 120 mg dose compared to placebo in patients with ACR(American College of Rheumatology)-defined fibromyalgia, co-morbid with…
- Conditions
- Depressive Disorder, Depression, Fibromyalgia
- Trial name
- NCT00264628
- Testing
- GW679769
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
One-third or more of individuals treated for major depressive disorder (MDD) do not experience remission of symptoms despite at least two adequate antidepressant trials.
- Trial name
- PAGE-1_AG1 (NCT01426516)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Genomind, LLC
Atopic Dermatitis
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients.
- Trial name
- DERMIND-AD (NCT07467564)
- Testing
- Dupilumab
- Where
- 7 sites in Qatar, Saudi Arabia and 1 more
- Volunteers
- 184 people
- Sponsor
- Sanofi
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111552
- Testing
- Escitalopram, Aripiprazole
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 237 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.